Imaging Test May Identify Biomarker of Alzheimer’s Disease
“Alzheimer’s is a grey matter disease,” notes Federica Agosta, MD, PhD, co-author of the study conducted at the Neuroimaging Research Unit, San Raffaele Scientific Institute in Milan, Italy. “However, white matter damage has a central role in how the disease strikes and progresses.”
AD is an irreversible, progressive brain disease that slowly destroys memory and thinking skills. Where or how the disease begins is not fully understood. Unlike late-onset AD that occurs after age 65 and is characterised primarily by progressive memory loss, patients with early-onset AD have impairment in several regions of the brain, including deficits in executive functioning and visuospatial abilities. Focal AD syndromes may cause visual disturbances or language deficits.
Researchers used DTI to identify similarities and differences in white tract damage across the AD spectrum and in relation to patterns of cortical atrophy, according to Dr. Agosta. DTI is a specialised magnetic resonance imaging technique that uses the movement of water molecules to characterise the microstructure of biological tissues. The technique is highly sensitive to white matter degeneration, she says.
Analysis of the images revealed that all of the patients had extensive white matter damage, and showed regional grey matter damage. “The white matter damage in patients with focal AD syndromes was much more severe and widespread than expected and cannot be explained solely by grey matter atrophy which was more localised,” Dr. Acosta points out.
She adds that the findings support the theory that AD pathology may travel along white matter fibres from one region of the brain to another.
In early-onset AD and atypical AD forms, "white matter degeneration may be an early marker that precedes grey matter atrophy,” Dr. Agosta says, adding that DTI has the potential to assess the extensive disorganisation of brain networks in focal AD even before overt cognitive deficits become apparent.
Top image. MR images of A, common and B, syndrome-specific patterns of cortical atrophy across the Alzheimer's disease variants.
Figure 2. Axial (left six columns) and sagittal (right column) MR images of fractional anisotropy results in patients with Alzheimer's disease variants relative to matched healthy control subjects.
Figure 3. Axial (left six columns) and sagittal (right column) MR images of mean diffusivity results in patients with Alzheimer's disease variants relative to matched healthy control subjects.
Source and image credit: RSNA
Published on : Wed, 27 May 2015
Print as PDF
The SonoSite SII features a new touchscreen user interface with a clinician-driven menu logic that adaptively adjusts to your imaging needs – “what you need, is what you see”. An embedded dual transducer connector allows you to quickly switch between...
Based on Mindray's new generation ultrasound platform, mQuadro, M9 has raised the industry standards to an all new level. Advanced signal transmission and reception processors provide highly sensitive and accurate echo detection. Innovative transducer...
Sectra provides a complete solution for primary diagnostics in pathology. The solution includes archiving and storage solutions together with high-end review workstations. It allows pathologists to make their diagnoses and reports with higher precision...
Powered by the most revolutionary ZONE Sonography® Technology, Resona 7’s new ZST+ platform brings the ultrasound image quality to a higher level by zone acquisition and channel data processing. Resona 7 also provides clinical research with the revolutionary...
Sectra offers solutions for capturing, storing and accessing virtually all images, video, audio and documents. Sectra VNA allows you to consolidate image handling, while ensuring clinical workflow efficiency, growth management and business continuity...